tedizolid and Peritonitis

BACKGROUND Mycobacterium abscessus is one of the most important mycobacteria, but its associated peritonitis in patients on continuous ambulatory peritoneal dialysis (CAPD) appears relative rare, and the treatment regimen of the antibiotics are still unclear. CASE REPORT A 38-year-old female with chronic glomerulonephritis on CAPD who was diagnosed with M. abscessus-associated peritonitis. Symptoms exacerbated despite treatment with a 3-antibiotic regimen combining clarithromycin, imipenem/cilastatin (IPM/CS), and minocycline (MINO). However, after changing IPM/CS and MINO to linezolid (LZD), her condition and inflammation improved, and she was able to be maintained on oral tedizolid (TZD). CONCLUSIONS Oxazolidinones such as LZD and TZD might be candidate antibiotics for the treatment of M. abscessus-associated diseases with chronic renal failure due to their immunomodulatory effects and non-renal excretion.

Topics: Adult; Anti-Bacterial Agents; Chronic Disease; Female; Glomerulonephritis; Humans; Immunocompromised Host; Linezolid; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Oxazolidinones; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis; Tetrazoles

In a mouse peritonitis model, tedizolid was comparable to linezolid and daptomycin against an

Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Daptomycin; Disease Models, Animal; Enterococcus faecalis; Enterococcus faecium; Female; Gram-Positive Bacterial Infections; Linezolid; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Oxazolidinones; Peritonitis; Staphylococcus; Tetrazoles